common glp-1 drugs Costs Explained: Managing Coverage Challenges Rx Trends: Real-World Data on

They include improved glomerular function, decreased renal atherosclerosis rates, increased natriuresis, decreased endothelin-dependent vasodilation, and an improvement in tubuloglomerular feedback [73]

This first wave of GLP-1s were commercially successful (Victoza saw peak sales of ~$3.8B in 2018), but results were modest relative to todays market

If you took a popular GLP-1 drug and now suffer from severe gastrointestinal issues, you are not alone

How much better

This distinction argues for careful long-term monitoring in peptide development programs, rather than suggesting that such risks are categorically greater than those of other modalities